HEALTH ECONOMIC EVALUATION OF PARICALCITOL AND COMBINATION OF CINACALCET WITH NON-SELECTIVE VITAMIN D IN PATIENTS WITH CHRONIC KIDNEY DISEASE 5D STAGE IN RUSSIAN FEDERA-TION
Abstract
AIM OF RESEARH: The objective of this study was to determine the cost effectiveness of intravenous paricalcitol versus combination cinacalcet+alfacalcidol in patients with chronic kidney dis-ease (CKD) in the health care setting in Russia in 2013. PATIENTS AND METHODS: This analysis is performed for patients on hemodialysis with diagnosed increased parathyroid hormone levels of above 300 pg/ml despite standard treatment consisting of die-tary restriction in phosphorus and calcium containing binders. A Markov process model was developed employing data sources from the published litera-ture, paricalcitol clinical trials, official Russian price/tariff lists and national population statis-tics. The primary perspective of the study was that of the national health care payer. The base case analysis is based on a 5-years time horizon. Clinical and economic outcomes were dis-counted at 5%. RESULTS: The use of paricalcitol leads to a cost saving of RUR 47,36 and an increase in life years gained (0.099 years) and a gain in QALYs (0.067). Consequently the use of paricalcitol is dominant over the use of combination cinacalcet+alfacalcidol. CONCLUSION: The results showed that the favourable clinical benefit of a intravenous parical-citol results in positive short and long-term health economic benefits in patients on hemodi-alysis. This study suggests that the use of paricalcitol in patients with severe chronic kidney disease may be cost-effective from the perspective of the national health insurance fund in Russia.
About the Authors
M. . Nuijten
Ars Accessus Medica
Russian Federation
Russian Federation
A. . Rudakova
St Petersburg State Chemical-Pharmaceutical Academy
Russian Federation
Russian Federation
T. . Marshall
AbbVie
Russian Federation
Russian Federation
References
1. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. 2005; 67(6): 2089-100.
2. K/DOQI guidelines,www.kidney.org/professionals/kdoqi/guidelines_bone/Guide8B.htm, accessed Feb 2nd, 2005
3. Alebiosu C.O., Ayodele O.E. The global burden of chronic kidney disease and the way forward // Ethn Dis. 2005;15(3): 418-23.
4. Dirks J.H., de Zeeuw D., Agarwal S.K., et al. International Society of Nephrology Com-mission for the Global Advancement of Nephrology Study Group 2004. Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration // Kidney Int. Suppl. 2005; 98: S1-6.
5. Stehman-Breen C.O., Sherrard D.J., Alem A.M. et al. Risk factors for hip fracture among patients with end-stage renal disease // Kidney Int. 2000; 58: 2200-2205.
6. Mazhar A.R., Johnson R.J., Gillen D. et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease // Kidney Int. 2001; 60: 324-332.
7. Ahmed S., O’Neill K.D., Hood A.F. et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells // Am. J. Kidney Dis. 2001; 37: 1267-1276.
8. Ganesh S.K., Stack A.G., Levin N.W. et al. Association of elevated serum PO4, Ca_PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients // J. Am. Soc. Nephrol. 2001; 12: 2131-2138.
9. Smirnov A.V. et al. National guidelines on CKD: general statements, definition, diagnostic, screening, approaches to prophylaxis and treatment // Nefrologiya. St-Petersburg, 2012.
10. Goodman W.G. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease // Semin. Dial. 2004; 17 (3): 209-16.
11. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphataemia and hyperparathyroidism in dialysis patients: recommendations for a change in management // Am. J. Kidney Dis. 2000; 35: 1226-1237.
12. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis // N. Engl. J. Med. 2000; 342: 1478-83.
13. Block G.A., Hulbert-Shearon T.E., Levin N.W., et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic HD patients: a national study // Am. J. Kidney Dis. 1998; 31: 607-617.
14. National recommendations on CKD-MBD. RDS working group // Nefrologija I Dializ 2011; 13 (1): 33-51.
15. Zandi-Nejad K., Brenner B.M. Strategies to retard the progression of chronic kidney dis-ease // Med. Clin. North Am. 2005; 89 (3): 489-509.
16. Nuijten M., Andress D.L., Marx S.E., Curry A.S., Sterz R. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model // Clin. Drug Investig. 2010; 30 (8): 545-57.
17. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2007 гг. (Аналитический отчет по данным Российского регистра заместительной почечной терапии // Нефрология и диализ 2009; 11 (3): 144233
18. Dobrez D., Mathes A., Amdahl M. et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings // Nephrol. Dial. Transplant. 2004; 5: 1174-1181.
19. Teng M., Wolf M., Lowrie E., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy // N. Engl. J. Med. 2003; 349: 446-56.
20. Cunningham J., Danese M.D., Olson K.A., Klassen P., Chertow G.M. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism // Kidney Int. 2005; 68: 1793-800.
21. Garside R., Pitt M., Anderson R., et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation // Health Technology Assessment 2007; 11 (18).
22. Ketteler M., Martin K.J., Wolf M., et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study // Nephrol Dial Transplant. 2012 Mar 19. [Epub ahead of print].
23. Roderick P., Nicholson T., Armitage A., et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales // Health Technol Assess. 2005; 9 (24): 1-178.
24. Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2012 г. (www.spboms.ru)
25. Nuijten M. Data management in modelling studies: the selection of data sources // PharmacoEconomics 1998; 3: 305-316.
26. Llach F., Velasquez-Forero F. Secondary Hyperparathyroidism in chronic renal failure; pathogenic and clinical aspects // Am. J. Kidney Dis. 2001; 38 (5): Suppl 5 S20-S33.
27. Goodman W.G. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease // Semin. Dial. 2004 May-Jun;17(3):209-16.
28. Urena Torres P. Clinical experience with cinacalcet HCl // Nephrol. Dial. Transplant. 2004 Aug;19 Suppl 5: V. 27-33.
Review
For citations:
Nuijten M., Rudakova A., Marshall T. HEALTH ECONOMIC EVALUATION OF PARICALCITOL AND COMBINATION OF CINACALCET WITH NON-SELECTIVE VITAMIN D IN PATIENTS WITH CHRONIC KIDNEY DISEASE 5D STAGE IN RUSSIAN FEDERA-TION. Nephrology (Saint-Petersburg). 2014;18(6):64-70. (In Russ.)
Views:
413
Email this article 